FMC (chemotherapy) | Wikipedia audio article
Channel: wikipedia tts
Date: 2019-06-06

This is an audio version of the Wikipedia Article:
https://en.wikipedia.org/wiki/FCM_(chemotherapy)





Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
https://assistant.google.com/services/invoke/uid/0000001a130b3f91
Other Wikipedia audio articles at:
https://www.youtube.com/results?search_query=wikipedia+tts
Upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts
Speaking Rate: 0.7504476537639042
Voice name: en-AU-Wavenet-D


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
FCM, or FMC in the context of chemotherapy is an acronym for a chemotherapy regimen that is often used in the treatment of indolent B cell non-Hodgkin's lymphomas. 
In combination with Rituximab this regimen is called R-FCM or R-FMC, or FCM-R, FMC-R. 
The [R]-FCM regimen contains 

(R)ituximab - anti-CD20 monoclonal antibody that can kill both normal and malignant CD20-bearing B cells;
(F)ludarabine  - an antimetabolite;
(C)yclophosphamide  - an alkylating antineoplastic agent from the oxazafosforine group;
(M)itoxantrone  - a synthetic antracycline analogue (antraquinone) that can intercalate DNA, thereby preventing cell division.The FCM or R-FCM regimen is also sometimes used in some autoimmune diseases that are inherently sensitive to the use of rituximab, fludarabine, mitoxantrone, and cyclophosphamide alone in monotherapies (e.g., in severe multiple sclerosis flares).